1 week Ago By ABMN Staff
Barclays PLC cut its holdings in shares of Dyne Therapeutics, Inc. ( NASDAQ:DYN – Free Report ) by 7.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC).
The fund owned 192,239 shares of the company’s stock after selling 15,070 shares during the period. Barclays PLC’s holdings in Dyne Therapeutics were worth $4,530,000 at the end of the most recent reporting period. Other large investors also recently bought and sold shares of the company.
Summit Investment Advisors Inc. boosted its holdings in shares of Dyne Therapeutics by 9.1% during the 4th quarter.
Summit Investment Advisors Inc. now owns 8,627 shares of the company’s stock valued at $203,000 after acquiring an additional 721 shares during the last quarter. Raymond James Financial Inc.
purchased a new stake in Dyne Therapeutics in the fourth quarter worth approximately $2,340,000. Springhill Fund Asset Management HK Co Ltd bought a new stake in Dyne Therapeutics in the 4th quarter worth approximately $3,091,000. Wells Fargo & Company MN raised its stake in Dyne Therapeutics by 54.
5% during the 4th quarter. Wells Fargo & Company MN now owns 38,754 shares of the company’s stock valued at $913,000 after buying an additional 13,677 shares during the last quarter. Finally, Trexquant Investment LP lifted its holdings in shares of Dyne Therapeutics by 95.
6% during the 4th quarter. Trexquant Investment LP now owns 125,378 shares of the company’s stock valued at $2,954,000 after buying an additional 61,288 shares during the period. 96.
68% of the stock is currently owned by institutional investors. Insider Activity In related news, insider Oxana Beskrovnaya sold 2,598 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $13.
95, for a total transaction of $36,242.10. Following the completion of the transaction, the insider now directly owns 199,087 shares of the company’s stock, valued at approximately $2,777,263.
65. This represents a 1.29 % decrease in their ownership of the stock.
The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link . Insiders sold a total of 6,237 shares of company stock worth $77,760 over the last 90 days. Corporate insiders own 20.
77% of the company’s stock. Dyne Therapeutics Stock Down 0.5 % Dyne Therapeutics ( NASDAQ:DYN – Get Free Report ) last released its earnings results on Tuesday, March 4th.
The company reported ($0.88) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.
04. Research analysts expect that Dyne Therapeutics, Inc. will post -3.
44 EPS for the current fiscal year. Wall Street Analysts Forecast Growth Several analysts recently commented on DYN shares. Piper Sandler cut their price objective on Dyne Therapeutics from $53.
00 to $48.00 and set an “overweight” rating for the company in a report on Friday, February 28th. Guggenheim reaffirmed a “buy” rating on shares of Dyne Therapeutics in a research report on Friday, January 24th.
JPMorgan Chase & Co. dropped their price objective on shares of Dyne Therapeutics from $18.00 to $17.
00 and set a “neutral” rating on the stock in a report on Friday, March 21st. Scotiabank initiated coverage on shares of Dyne Therapeutics in a report on Friday, March 7th. They set a “sector outperform” rating and a $50.
00 target price for the company. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $45.00 price target on shares of Dyne Therapeutics in a research note on Tuesday, January 14th.
One research analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Dyne Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $47.
46. Check Out Our Latest Stock Analysis on DYN Dyne Therapeutics Company Profile ( Free Report ) Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Further Reading Want to see what other hedge funds are holding DYN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dyne Therapeutics, Inc. ( NASDAQ:DYN – Free Report ).
Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
